We tested this possibility by mixing MB with the Bcl-2 inhibitor ABT-737 (at a 20:1 and 5:1 ratio according to their respective IC50s for MOLM13 and KG-1A cells, respectively) to treat AML cells. Here, BCL2 is linked to acute myeloid leukemia.